myotubularin related protein 2Genealiases: CMT4B · CMT4B1
Q-omics provides the consensus-scored MTMR2 profile across patient tissues and cancer cell-line models. MTMR2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTMR2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MTMR2 protein abundance shows 35,564 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where MTMR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTMR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTMR2 survival associations across molecular data types. MTMR2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTMR2 RNA expression–survival associations across cancer types. High MTMR2 expression shows unfavorable associations in ACC, LIHC, MESO, CESC and BLCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTMR2 RNA expression.
This table summarizes MTMR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MTMR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTMR2 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, KIRC, LIHC and CHOL. The HNSC box plot shows higher MTMR2 RNA expression in tumor versus normal tissue (log2 FC = +0.878, t-test p < 0.001).
This table shows molecular features associated with MTMR2 in patient tissues and cancer cell lines. In patient samples, MTMR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTMR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
